X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the Licensing Agreement, OncoVerity will optimize JNJ-74494550 (cusatuzumab), a first-in-class anti-CD70 antibody, in acute myeloid leukemia (AML) and explore its application in other cancers.
Lead Product(s): Cusatuzumab,Azacitidine
Therapeutic Area: Oncology Product Name: JNJ-74494550
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: OncoVerity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 27, 2023
Details:
The net proceeds will be used for the continued development JNJ-74494550 (cusatuzumab), a first-in-class anti-CD70 antibody for the treatment of acute myeloid leukemia (AML).
Lead Product(s): Cusatuzumab,Azacitidine
Therapeutic Area: Oncology Product Name: JNJ-74494550
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 27, 2023
Details:
The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia.
Lead Product(s): Cusatuzumab,Azacitidine
Therapeutic Area: Oncology Product Name: JNJ-74494550
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination June 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
